TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24021217

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with low-expressing serotonin transporter genotype
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with high-expressing serotonin transporter genotype
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with low-transcription 1A receptor genotype
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with high-expressing genotypes in serotonin transporter, 1A, or 2A receptors
Number of subjects: 177
Study: 22009189

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 90
Study: 19400893

Group type: EXPERIMENTAL
Intervention: Hookworm infection (10 hookworm larvae)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 30
Study: 17692137

Group type: EXPERIMENTAL
Intervention: Fermented milk with probiotics (Bifidobacterium longum BB536, Bifidobacterium spp. 420 and Lactobacillus acidophilus 145)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fermented milk with probiotics and inulin (4 g)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control fermented milk
Number of subjects: 66
Study: 15958324

Group type: EXPERIMENTAL
Intervention: Complex Hongyibuxue oral solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 100
Study: 12021222

Group type: EXPERIMENTAL
Intervention: Coronary stenting in unstable angina
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Bypass surgery in unstable angina
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Coronary stenting in stable angina
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Bypass surgery in stable angina
Number of subjects: 1205
Study: 9698951

Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg.kg-1 i.v. preoperative
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg.kg-1 i.v. postoperative
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7599807

Group type: EXPERIMENTAL
Intervention: -15 cm H2O Continuous Negative Pressure (CNP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: -20 cm H2O Continuous Negative Pressure (CNP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +15 cm H2O Positive End-Expiratory Pressure (PEEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: -10 cm H2O Continuous Negative Pressure (CNP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: +10 cm H2O Positive End-Expiratory Pressure (PEEP)
Number of subjects: 0
Study: 2240674

Group type: EXPERIMENTAL
Intervention: 400-micrograms clonidine bolus followed by 10 micrograms/h clonidine infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 800-micrograms clonidine bolus followed by 20 micrograms/h clonidine infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline bolus followed by 24-h saline infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 micrograms/h clonidine infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400-micrograms clonidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 800-micrograms clonidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60
Study: 13230

Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 14
Study: 30170012

Group type: EXPERIMENTAL
Intervention: Exparel (Liposomal Bupivacaine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 79
Study: 27697570

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 100
Study: 25841300

Group type: EXPERIMENTAL
Intervention: Saxagliptin-metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acarbose-metformin
Number of subjects: 0
Study: 24011551

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 24910

Group type: COMPARATOR
Intervention: Control (clopidogrel or placebo)
Number of subjects: 24910
Study: 21354682

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (1 tablet containing 1,000 mg of elemental lanthanum)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (three 800-mg tablets)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard meal alone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 31
Study: 19390210

Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Creatinine-based formulae
Number of subjects: 50
Study: 17069768

Group type: EXPERIMENTAL
Intervention: Prazosin (13.3 +/- 3 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15279523

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exposure group therapy without explicit cognitive interventions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait‐list control condition
Number of subjects: 90
Study: 11493040

Group type: EXPERIMENTAL
Intervention: Tailored letter providing feedback on consumption of target foods, stage‐matched nutrition education booklets, diet‐health endorsement from PCPs, and two motivational counseling telephone calls.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 230
Study: 9506731

Group type: EXPERIMENTAL
Intervention: 50 mg prednisolone daily for 3.7 +/- 0.6 months (range, 1-6)
Number of subjects: 9
Study: 7511357

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study: 2893592

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (50 micrograms subcutaneously prior to meal ingestion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30580089

Group type: EXPERIMENTAL
Intervention: Supervised Pelvic Floor Muscle Training (PFMT) and biofeedback plus conservative treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Attention-control massage treatment plus conservative treatment
Number of subjects: 98
Study: 28735217

Group type: EXPERIMENTAL
Intervention: 5mg zopiclone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10mg zopiclone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both doses (5mg and 10mg zopiclone)
Number of subjects: 16
Study: 25987795

Group type: EXPERIMENTAL
Intervention: Fructose-reduced diet (FRD)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Fructose-reduced diet (FRD) with provocation test
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Fructose breath tests (FBT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no FRD)
Number of subjects: 182
Study: 24352393

Group type: EXPERIMENTAL
Intervention: Allogeneic bone graft
Number of subjects: 48

Group type: COMPARATOR
Intervention: No allogeneic bone graft (Control)
Number of subjects: 48
Study: 21804212

Group type: COMPARATOR
Intervention: Silodosin 2 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Silodosin 4 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Silodosin 8 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Silodosin 12 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg (multiple dosing)
Number of subjects: 82
Study: 19699835

Group type: EXPERIMENTAL
Intervention: Ready-to-eat (RTE) cereal consumption
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Higher RTE cereal consumption in boys
Number of subjects: 660

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 660
Study: 16404360

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 7) followed by docetaxel 100 mg/m² (arm A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² with irinotecan 200 mg/m² (arm B)
Number of subjects: 100
Study: 15600582

Group type: EXPERIMENTAL
Intervention: Parasympathetic Nervous System (PNS) suppression due to congestive heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sympathetic Nervous System (SNS) suppression due to primary autonomic failure
Number of subjects: 0
Study: 11213074

Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on gender (female vs male)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on race (Asian males vs white males)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on history of noncompliance
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on cardiac ejection fraction
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on HIV infection
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Recommendation for renal transplantation based on weight
Number of subjects: 271
Study: 9516095

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate MDI (2,000 microg with Babyhaler spacer)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate MDI
Number of subjects: 17
Study: 8034840

Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adrenalized solutions (with epinephrine 1:200,000)
Number of subjects: 20
Study: 2662099

Group type: EXPERIMENTAL
Intervention: Long-acting gas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone oil
Number of subjects: 0
Study: 31413008

Group type: EXPERIMENTAL
Intervention: Fused CT-MR imaging datasets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uncoregistered images
Number of subjects: 20
Study: 28651865

Group type: EXPERIMENTAL
Intervention: Echolucent plaques
Number of subjects: 894

Group type: COMPARATOR
Intervention: Non-echolucent plaques
Number of subjects: 894
Study: 24821259

Group type: EXPERIMENTAL
Intervention: Nonintubated VATS under epidural anesthesia
Number of subjects: 354

Group type: COMPARATOR
Intervention: VATS under general anesthesia with double lumen tube
Number of subjects: 354
Study: 23558603

Group type: EXPERIMENTAL
Intervention: Generic DPI
Number of subjects: 103

Group type: COMPARATOR
Intervention: Diskus®
Number of subjects: 103
Study: 21679322

Group type: EXPERIMENTAL
Intervention: 12-week guided skiing programme (IG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study: 19564260

Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotics
Number of subjects: 2659

Group type: EXPERIMENTAL
Intervention: Nonstudy antibiotics
Number of subjects: 2659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2659
Study: 16481637

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 10
Study: 15542236

Group type: EXPERIMENTAL
Intervention: Words with high-frequency first syllables
Number of subjects: 0

Group type: COMPARATOR
Intervention: Words with low-frequency first syllables
Number of subjects: 0
Study: 12776814

Group type: EXPERIMENTAL
Intervention: Antiprex (Elpen, Greece) 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Renitec (Vianex, Greece) 20 mg
Number of subjects: 24
Study: 11210156

Group type: EXPERIMENTAL
Intervention: Lower lateral lasers for patient set-up
Number of subjects: 16
Study: 8831919

Group type: EXPERIMENTAL
Intervention: Ciprofibrate, 100 mg/day once daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Gemfibrozil, 1200 mg/day twice daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ciprofibrate and Gemfibrozil
Number of subjects: 110
Study: 1314922

Group type: EXPERIMENTAL
Intervention: Neutrophil chemotactic factors measured in coronary sinus effluents from patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Plain cardioplegic solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Formyl‐methionyl‐leucyl‐phenylalanine (positive control)
Number of subjects: 6
Study: 3893007

Group type: EXPERIMENTAL
Intervention: sc human growth hormone
Number of subjects: 10

Group type: COMPARATOR
Intervention: im growth hormone therapy
Number of subjects: 10
Study: 2454358

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 31343094

Group type: EXPERIMENTAL
Intervention: ETC-206, an oral Mnk 1/2 kinase inhibitor
Number of subjects: 0
Study: 31281938

Group type: EXPERIMENTAL
Intervention: Exercise intervention program (prescribed exercises three times/week for one year)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (routine physical activities for one year)
Number of subjects: 52
Study: 28388888

Group type: EXPERIMENTAL
Intervention: NDI-U
Number of subjects: 76
Study: 26048277

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV every 2 weeks)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV every 2 weeks) + Paclitaxel (80 mg/m² on days 1, 8, and 15 of 28-day cycles)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study: 23204513

Group type: EXPERIMENTAL
Intervention: Cluster randomised controlled trial (RCT) design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-methods quasiexperimental evaluation
Number of subjects: 0
Study: 21451004

Group type: EXPERIMENTAL
Intervention: DNA prime and subunit envelope protein boost (gag and env DNA adsorbed to polylactide coglycolide microspheres followed by recombinant trimeric envelope glycoprotein in MF59 adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA prime and subunit envelope protein boost
Number of subjects: 0
Study: 20084841

Group type: EXPERIMENTAL
Intervention: Intensive education group (3 home visits focused on home environment modification)
Number of subjects: 383

Group type: COMPARATOR
Intervention: General health education and smoking cessation advice (Control group)
Number of subjects: 383
Study: 16713143

Group type: EXPERIMENTAL
Intervention: Conventional-dose HT (2 mg 17beta-estradiol + 1 mg NETA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low-dose HT (1 mg 17beta-estradiol + 0.5 mg NETA)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 202
Study: 15757308

Group type: EXPERIMENTAL
Intervention: Reserving and reinfusing 24% of calculated circulating blood volume (CBV) of autoblood
Number of subjects: 61

Group type: COMPARATOR
Intervention: Reserving and reinfusing 12% of calculated circulating blood volume (CBV) of autoblood
Number of subjects: 61
Study: 11282903

Group type: EXPERIMENTAL
Intervention: Intracoronary insulin infusion
Number of subjects: 26
Study: 9272389

Group type: EXPERIMENTAL
Intervention: Lansoprazole alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lansoprazole plus amoxicillin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 7933686

Group type: EXPERIMENTAL
Intervention: 99mTc‐MAG3
Number of subjects: 0

Group type: COMPARATOR
Intervention: 123I‐OIH
Number of subjects: 0
Study: 3060612

Group type: EXPERIMENTAL
Intervention: Ketoprofen (200-300 mg/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Indomethacin (100-150 mg/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ketoprofen (200-300 mg/day) and Indomethacin (100-150 mg/day)
Number of subjects: 140
Study: 31615467

Group type: EXPERIMENTAL
Intervention: EmpaTeach intervention
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 2000
Study: 27922028

Group type: EXPERIMENTAL
Intervention: Lubiprostone (48 mcg per day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lubiprostone and Placebo
Number of subjects: 76
Study: 25452054

Group type: EXPERIMENTAL
Intervention: Secondhand tobacco smoke (SHS) prevention program based on the Health Belief Model (HBM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard government-mandated counseling care
Number of subjects: 100
Study: 22731632

Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine (CHX) dental varnish
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 21218307

Group type: EXPERIMENTAL
Intervention: Consistent methadone treatment
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Further education
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fewer relationship disruptions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Treatment for depression
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Skills for avoiding and refusing drugs, coping with stress, and maintaining recovery-supportive friendships
Number of subjects: 144
Study: 19769830

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen/codeine 600/60 mg
Number of subjects: 0
Study: 17027436

Group type: EXPERIMENTAL
Intervention: Oily fish (4.5 g eicosapentaenoic acid + docosahexanoic acid)
Number of subjects: 142

Group type: COMPARATOR
Intervention: White fish (0.7 g eicosapentaenoic acid + docosahexanoic acid)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study: 12717871

Group type: COMPARATOR
Intervention: Asthma medication including inhaled salbutamol 200 microg four times a day and budesonide 400 microg twice a day for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Asthma medication plus antireflux therapy including oral omeprazole 20 mg once a day and domperidone 10 mg three times a day for 6 weeks
Number of subjects: 30
Study: 11157692

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg on days 1 and 2 and 0.4 g/kg on days 14 and 28
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 59
Study: 9159358

Group type: EXPERIMENTAL
Intervention: Inversion-recovery technique to map T1 transversely at the level of the basal ganglia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Childhood (mean age 7.1 +/- 1.4) to adolescence (mean age 13.5 +/- 2.6)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adolescence (mean age 13.5 +/- 2.6) to adulthood (mean age 26.5 +/- 3.4)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 50
Study: 7903211

Group type: EXPERIMENTAL
Intervention: Tertatolol (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tertatolol (5 mg) and Prazosin (1 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Prazosin (1 mg)
Number of subjects: 8
Study: 3425213

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg FDDF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg FDDF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31158110

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus cognitive behavioral therapy
Number of subjects: 22
Study: 28479170

Group type: EXPERIMENTAL
Intervention: Minimally invasive risk-reduction surgery (hysterectomy plus bilateral salpingo-oophorectomy or BSO alone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Minimally invasive risk-reduction surgery
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Presence of occult cancer
Number of subjects: 85
Study: 25787915

Group type: EXPERIMENTAL
Intervention: bortezomib/cyclophosphamide/dexamethasone (VCD)
Number of subjects: 504

Group type: COMPARATOR
Intervention: bortezomib/doxorubicin/dexamethasone (PAd)
Number of subjects: 504
Study: 23978275

Group type: EXPERIMENTAL
Intervention: Preoperative education seminar and standard information brochure
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard information brochure
Number of subjects: 204
Study: 21255627

Group type: EXPERIMENTAL
Intervention: 1% whey protein beverage (5 g, 93 kJ)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2% whey protein beverage (10 g, 178 kJ)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4% whey protein beverage (20 g, 348 kJ)
Number of subjects: 50
Study: 19505883

Group type: EXPERIMENTAL
Intervention: Medical therapy plus CRT
Number of subjects: 813

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 813
Study: 17321570

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (200 microg PM(2.5)/m(3))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (100 microg PM(2.5)/m(3))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (0 microg PM(2.5)/m(3))
Number of subjects: 13
Study: 15465230

Group type: EXPERIMENTAL
Intervention: Augmented external fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous pinning and casting
Number of subjects: 50
Study: 11505534

Group type: EXPERIMENTAL
Intervention: Doxazosin (Cardura)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9427903

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A therapy
Number of subjects: 0
Study: 8487050

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy and carmustine (BCNU)
Number of subjects: 778
Study: 3301079

Group type: EXPERIMENTAL
Intervention: 1 mg intravenous dose of captopril
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous dose of captopril
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 25 mg intravenous dose of captopril
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle of captopril (control)
Number of subjects: 5